English
This article is from The Journal of Biological Chemistry , volume 289 . Abstract Background: Unregulated plasma kallikrein proteolytic activity can result from C1-inhibitor deficiency, causing excessive and potentially fatal edema.Results: The antibody DX-2930 potently and specifically inhibits plasma kallikrein and exhibits a long plasma half-life.Conclusion: An antibody protease inhibitor can lead to potent and specific bioactivity.Significance: DX-2930 could be an effective therapeutic for the prophylactic inhibition of plasma kallikrein-mediated diseases.
Sign in with your free account to read, download EPUBs or listen.
Ebook · Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody. · Kenniston, Jon A., Faucette, Ryan R., Martik, Diana, Comeau, Stephen R., Lindberg, Allison P., Kopacz, Kris J., Conley, Gregory P., Chen, Jie · Internet Archive